Studies in 2010 funded in part by the U.S. Department of Defense's Joint Project Manager Transformational Medical Technologies office showed "100 percent protection from an otherwise lethal dose of Zaire Ebola virus," according to Tekmira's website. Scientists racing to develop something that will stop the largest Ebola epidemic in history are trying a variety of experimental drugs on patients. 'Extraordinary' race for Ebola vaccine raises ethical questions ZMapp Mapp Biopharmaceutical Inc. is in the early stages of developing its drug, ZMapp. But antiviral drugs can be used to treat a wide variety of diseases. In January, Tekmira started phase I clinical trials on the drug, testing it on a small number of human subjects.